The Growing Threat of Catheter-Associated Urinary Tract Infections in Urology

Catheter-associated urinary tract infections, commonly known as CAUTIs, pose a major challenge in urological care, particularly following procedures such as prostate surgery, kidney stone removal, or bladder interventions. These infections occur when bacteria colonize the catheter surface, forming biofilms that are notoriously difficult to eradicate. In the UK, urinary catheters are used in approximately 10-25% of hospitalized patients, with CAUTIs accounting for up to 75% of hospital-acquired urinary tract infections. This not only prolongs hospital stays but also contributes to the rising tide of antibiotic resistance, a critical public health concern.

Urology procedures often require temporary or long-term catheterization to manage urine flow and prevent complications like obstruction. However, standard silicone catheters provide an ideal environment for pathogens like Escherichia coli and Proteus mirabilis to adhere, multiply, and form crystalline biofilms leading to blockages and symptomatic infections. Traditional prevention strategies, including antibiotic prophylaxis and meticulous hygiene protocols, have limitations, as bacteria within biofilms can survive at concentrations 1000 times higher than free-floating cells, rendering many antibiotics ineffective.

Innovative Solution: The Bacteriaphobic Coating Technology Behind Camstent

Enter Camstent Coated Catheters, featuring a patented micro-thin polymer coating known as Bacteriaphobic. Unlike antibiotic-impregnated devices that release drugs and risk fostering resistance, this non-leaching coating works by altering the surface chemistry to repel proteins and prevent bacterial attachment from the outset. Developed through high-throughput polymer screening, the technology creates a 'non-stick' surface analogous to Teflon for frying pans, but tailored for medical implants.

The coating's efficacy stems from combinatorial chemistry, where thousands of polymers are tested for resistance to fibrinogen adsorption—the initial step in biofilm formation. This approach, pioneered at the University of Nottingham, identified materials that inhibit adhesion without biocidal action, preserving the body's microbiome and minimizing resistance risks.

University of Nottingham's Pivotal Role in Translational Research

The University of Nottingham stands at the forefront of this innovation, with researchers from the Schools of Pharmacy, Life Sciences, and Chemical Engineering driving the discovery and optimization. Professor Morgan Alexander led the initial high-throughput screening published in Nature Biotechnology in 2012, identifying the core polymer family. Professor Paul Williams contributed microbiology expertise on biofilm dynamics, while Professor Derek Irvine from Chemical Engineering overcame commercialization hurdles, such as ensuring catheter flexibility, shelf-life stability, and scalable manufacturing.

Dr. Andrew Hook, a key research fellow, advanced the materials through Wellcome Trust-funded projects. This interdisciplinary collaboration exemplifies how UK universities bridge academia and industry, with Camstent Ltd licensing the technology and achieving CE and UKCA marking. Nottingham's Bioscience Technical Facility and Molecular Microbiology Department analyzed pilot study samples, confirming 95% reductions in biofilm and mineralization.

Such translational success underscores Nottingham's impact, shortlisted for Times Higher Education awards and contributing to REF case studies on real-world health improvements.

Design and Methodology of the Landmark Multicenter Clinical Trial

The pivotal study, published on April 3, 2026, in the open-access journal Antibiotics, was a prospective, multicenter randomized controlled trial (NCT04461262) across UK sites including Norfolk & Norwich University Hospital and Stoke Mandeville Hospital. Enrolling 200 patients (intention-to-treat), it compared Camstent Coated Catheters (CCC) to standard uncoated silicone catheters (SC) in adults requiring indwelling urethral catheterization for 7-28 days post-urology procedures or for long-term management.

Patients were stratified by age and gender, randomized 1:1, with urine cultures (>10⁵ CFU/mL defining bacteriuria) at days 0, 3, 5, 7, 10, 14, 21, and 28. Primary endpoints focused on time to infection, days infected, and incidence; secondary included symptomatic CAUTIs, antibiotic use, discomfort, and blockages. Statistical power was 90% to detect reductions, using Hodges-Lehmann estimators and Fisher's exact tests.

The per-protocol cohort (188 patients) split into primary (107 newly catheterized uninfected hospital patients) and secondary (81 long-term asymptomatic bacteriuria community patients), reflecting real-world urology scenarios.

Striking Results: Significant Reductions in Infections and Antibiotic Needs

Results were compelling. Colonization-free rates favored CCC: 79% vs 46% at day 7 (p=0.016), 69% vs 39% at day 14. Mean infected days in first 14: 3 vs 4.6 (p=0.0117). Infection incidence at day 14: 33% vs 50%.

• In the secondary cohort, symptomatic CAUTIs: 0% (CCC) vs 20% (SC), p=0.0054; median time to symptoms in SC: 9 days.
• Across per-protocol: symptomatic infections 4% vs 20% (p=0.0007); median time 13.5 vs 7 days.
• UTI antibiotic use: 4% vs 21%.

While blockages were higher in CCC (13% vs 1%), likely due to less encrustation masking issues, patient discomfort during insertion/removal was comparable, with no severe events. Adverse events were mild-moderate (37%), none life-threatening.

These outcomes translate to a third fewer infections and halved antibiotic prescriptions, vital amid UK antimicrobial resistance where CAUTIs drive overuse.

Implications for NHS Urology Practice and Patient Outcomes

For the NHS, where CAUTIs cost millions annually in extended stays and treatments—estimated £99-£161 million yearly—this innovation promises savings and better outcomes. Post-urology patients, often elderly or comorbid, face heightened risks; CCCs could shorten recovery, reduce readmissions, and enhance quality of life by minimizing pain, fever, and sepsis threats.

Long-term users, like those with spinal injuries or chronic retention, benefit most—no symptomatic infections in the trial's secondary cohort highlights potential for community care transformation. Integration into NHS supply chains via Pennine Healthcare positions CCCs for widespread adoption.

Combating Antibiotic Resistance: A University-Led Stewardship Advance

Antibiotic resistance exacerbates CAUTI challenges; E. coli strains resistant to multiple drugs are rising in UK hospitals. By preventing biofilm without antibiotics, Camstent supports stewardship goals, aligning with UKHSA and WHO priorities. Nottingham's non-biocidal approach avoids selective pressure, preserving efficacy of last-resort drugs.

This reflects broader UK university efforts in medtech, where academic discoveries address global health crises.

Patient Perspectives and Real-World Case Studies

Patient-reported outcomes showed similar comfort levels, but fewer antibiotic courses mean less gastrointestinal side effects and resistance risks. Anecdotal pilot feedback noted easier handling due to smoother surfaces. In urology wards, reduced CAUTIs could alleviate nursing burdens, allowing focus on holistic care.

Future Directions: Ongoing Trials and Commercial Scale-Up

Camstent plans Notified Body submissions for expanded claims, with larger trials underway. Nottingham continues analysis and next-gen coatings for stents. Partnerships like with University of York expand applications to central lines and ventilators.

Global potential is immense; with 450,000 long-term UK users and millions worldwide, this could save lives and billions.

Broader Impact on UK Higher Education and MedTech Innovation

Nottingham's journey—from lab screening to clinical validation—exemplifies REF-impacting research. Funding from Wellcome Trust and Impact Accelerators enabled spin-out success, creating jobs and IP. It inspires interdisciplinary models, vital for UK universities amid funding pressures, positioning academia as healthcare innovators.

Stakeholders, including clinicians like Mark Rochester, praise the tech's translation, urging adoption.

Expert Insights and Stakeholder Perspectives

Mark Harwood, Camstent CEO: "Millions of catheters used weekly; this could transform infection control." Prof. Irvine highlights engineering feats enabling market readiness. Urology experts note alignment with NICE guidelines on CAUTI prevention.

Outlook: Paving the Way for Safer Urological Care

The Camstent study heralds a new era, where university ingenuity curtails a pervasive clinical scourge. As adoption grows, UK patients stand to gain from fewer infections, less antibiotics, and superior outcomes—testament to Nottingham's enduring legacy in biomedical innovation.

Photo by Mike Smith on Unsplash